After a bruising regulatory saga, the company submitted AMT-130 — a one-time, brain-delivered gene therapy that slowed disease progression over three years — for accelerated approval.
The company helps patients steer through cancer care — and is now building a broader oncology group backed by Humana, CVS and JPMorgan’s Morgan Health.
The GLP-1 drug behind Ozempic and Wegovy lengthened lifespan and improved muscle, memory and inflammation in old mice — and the benefits weren’t explained by calorie cutting alone.
Harvard researchers converted human pancreatic duct cells into insulin-making “beta-like” cells by disabling a single gene — a potential new route to replacing what diabetes destroys.
In a Phase 3 trial, pulmonary-artery denervation cut clinical worsening roughly in half for patients whose heart failure had driven up pressure in the lungs’ arteries.
There’s no approved drug for celiac disease — only a strict gluten-free diet. Teva’s experimental TEV-408 significantly reduced gluten-triggered intestinal damage in a mid-stage study.
The deal buys rights to an early-stage “tri-specific” antibody built to hit B cells — drivers of many autoimmune conditions — from multiple angles at once.
A decade-long study found that obesity imprints durable molecular marks on immune cells that can persist for years after people slim down, which may help explain lingering health risks.
Groups representing pediatricians, family doctors and OB-GYNs released their own respiratory-season recommendations — including an extended RSV-vaccine window for pregnancy.
Takotsubo syndrome mimics a heart attack but involves no blocked arteries. A new score using blood markers and sex identified it with nearly 90% accuracy — before invasive testing.
The long-acting interferon, already used for a related blood cancer, beat an older drug at controlling platelet counts and cutting clot-related events in a Phase 3 trial.
MIT researchers built a detailed atlas of the striatum — the brain’s hub for movement, habit and reward — pinpointing neuron types uniquely vulnerable in Huntington’s and addiction.